홈P8A • SGX
add
Cordlife Group Ltd
시장 뉴스
재무
손익계산서
수익
순이익
(SGD) | 2024년 6월info | 전년대비 변동 |
---|---|---|
수익 | 459.50만 | -67.54% |
운영비 | 859.05만 | -6.80% |
순이익 | -617.80만 | -655.33% |
순이익률 | -134.45 | -1,810.56% |
주당 수익 | — | — |
EBITDA | -683.90만 | -615.37% |
유효 세율 | 8.73% | — |
대차대조표
총자산
총부채
(SGD) | 2024년 6월info | 전년대비 변동 |
---|---|---|
현금 및 단기 투자 | 5954.00만 | -15.89% |
총자산 | 2.24억 | -4.16% |
총부채 | 1.01억 | 3.31% |
총자기자본 | 1.23억 | — |
발행 주식 | 2.56억 | — |
주가순자산비율 | 0.32 | — |
총자산이익률 | -8.79% | — |
자본이익률 | -15.66% | — |
현금 흐름
순현금흐름
(SGD) | 2024년 6월info | 전년대비 변동 |
---|---|---|
순이익 | -617.80만 | -655.33% |
영업 현금 흐름 | -295.10만 | -192.71% |
투자 현금 흐름 | 290.45만 | 258.76% |
자금 조달 현금 흐름 | -54.95만 | -19.59% |
순현금흐름 | -49.80만 | -153.06% |
잉여 현금 흐름 | -465.36만 | -1,473.26% |
정보
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
CEO
설립
2001. 5. 2.
웹사이트
직원 수
111